3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
6
Head & Neck
2
Gynecologic
2
Breast
2
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Conditions
Melanoma
250
Uveal Melanoma
29
Neoplasm Metastasis
22
Skin Neoplasms
17
Brain Neoplasms
17
Carcinoma, Non-Small-Cell Lung
15
Carcinoma, Merkel Cell
10
Neoplasms
9
Carcinoma, Renal Cell
9
Squamous Cell Carcinoma of Head and Neck
8
Triple Negative Breast Neoplasms
7
Carcinoma, Hepatocellular
7
Uterine Cervical Neoplasms
6
Colorectal Neoplasms
6
Carcinoma, Transitional Cell
6
Urinary Bladder Neoplasms
5
Stomach Neoplasms
5
Lung Neoplasms
5
Diabetes Mellitus, Insulin-Dependent, 12
5
Small Cell Lung Carcinoma
4
Ovarian Neoplasms
4
Kidney Neoplasms
4
Carcinoma, Basal Cell
4
Sarcoma
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Non-Hodgkin
3
Liver Neoplasms
3
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Vulvar Neoplasms
2
Interventions
montanide ISA 51
1
Ritonavir
1
Radiotherapy
1
Mohs Surgery
1
Mass Spectrometry
1
Ipilimumab
1
Interleukin-2
1
Indinavir
1
Chromatography, High Pressure Liquid
1
BI 2536
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
Ipilimumab
×
Dermatologic
×
Clear all
NCT03752398
2024-07-05
DUET-3
Xencor, Inc.
Phase 1
Completed
198 enrolled